White Paper · Advisory

Pharma & Life-Sciences Software Licensing

How validation, Part 11 and serialization mandates — not user counts — drive the true cost of a life-sciences software estate.

Format PDF + HTML

Read Time 20 Minutes

Last Updated July 14, 2026

Validation, not seats: why GxP status and validated-environment chains dominate licensing economics in pharma.
CSV to CSA: how the risk-based Computer Software Assurance shift changes the cost of every system you license.
The environment multiplier: how prod, validation, non-prod and DR chains turn one license into four cost centres.
System sprawl: where LIMS, MES, QMS, eTMF, RIM, PV, CTMS and serialization each hide their own licensing and validation burden.
Over-scoped Part 11: the systematic over-buy patterns an independent buyer side review reliably recovers.

500+Enterprise Clients

$2B+Under Advisory

11Vendor Practices

100%Buyer Side

Free Download

Get the full white paper

Email gated. Corporate addresses only.

Ready?

Stop overpaying. Start negotiating.

Independent. Buyer side. The advisory firm enterprise software vendors do not want you to hire.